High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

Blood

Volumn 98, Issue 6, 2001, Pages 1721-1726

  Dearden, Claire E ^{a,b,c,d,e,f,g,h,i,j,k,l}   Matutes, Estella ^{a,b,c,d,e,f,g,h,i,j,k}   Cazin, Bruno ^{a,b,c,d,e,f,g,h,i,j,k}   Tjønnfjord, Geir E ^{a,b,c,d,e,f,g,h,i,j,k}   Parreira, Antonio ^{a,b,c,d,e,f,g,h,i,j,k}   Nomdedeu, Benet ^{a,b,c,d,e,f,g,h,i,j,k}   Leoni, Pietro ^{a,b,c,d,e,f,g,h,i,j,k}   Clark, Fiona J ^{a,b,c,d,e,f,g,h,i,j,k}   Radia, Deepti ^{a,b,c,d,e,f,g,h,i,j,k}   Rassam, Saad M B ^{a,b,c,d,e,f,g,h,i,j,k}   Roques, Tony ^{a,b,c,d,e,f,g,h,i,j,k}   Ketterer, Nicolas ^{a,b,c,d,e,f,g,h,i,j,k}   Brito Babapulle, Vasantha ^{a,b,c,d,e,f,g,h,i,j,k}   Dyer, Martin J S ^{a,b,c,d,e,f,g,h,i,j,k}   Catovsky, Daniel ^{a,b,c,d,e,f,g,h,i,j,k}  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Oncologic Institute   (Portugal)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h Department of Microbiology Greenwich Hospital   (United Kingdom)

ⁱ QUEEN MARY S HOSPITAL   (United Kingdom)

^j Barnsely District General Hospital   (United Kingdom)

^k Multidisciplinary Oncology Centre (CePO)   (Switzerland)

^l ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHYLPREDNISOLONE; MITOXANTRONE; PENTOSTATIN; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ALLOGRAFT; ARTICLE; AUTOTRANSPLANTATION; CLINICAL ARTICLE; DEATH; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; LEUKEMIA REMISSION; MALE; NAUSEA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RIGOR; STEM CELL TRANSPLANTATION; SURVIVAL TIME; T CELL LEUKEMIA; THROMBOCYTOPENIA; URTICARIA;

EID: 0035885965     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1721     Document Type: Article

References (21)

1. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood. 1991;78:3269-3274.
2. Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Br J Haematol. 1998;103:488-494.
3. Riechmann L, Clark MR, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323-327.
4. Gilleece MH, Dexter TM. Effects of CAMPATH-1H antibody on human haemopoietic progenitors in vitro. Blood. 1993;82:807-812.
5. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H, Leuk Res. 1998;22:185-191.
6. Hale G, Dyer MJS, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody, CAMPATH-1H. Lancet. 1988;ii:1395-1401.
7. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1H antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431-1439.
8. Pawson R, Dyer MJS, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15:2667-2672.
9. Kotteridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
10. Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994;12:2588-2593.
11. Collins RH, Pineiro LA, Agura ED, Fay JW. Treatment of T prolymphocytic leukaemia with allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;21:627-628.
12. Ośterborg A, Fassas AS, Anagnostopoulos A, et al. Humanised CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93:151-153.
13. Osterborg A, Dyer MJS, Bunjes D, at al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. J Clin Oncol. 1997;15:1567-1574.
14. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic leukaemia. Br J Haematol. 1997;96:617-619.
15. Dyer MJS, Kelsey SM, Mackay HJ, et al. In vivo 'purging' of residual disease in CLL with CAMPATH-1H. Br J Haematol. 1997;97:669-672.
16. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodkin's lymphoma. J Clin Oncol. 1998;16:3257-3263.
17. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:4491-4508.
18. Yuille MA, Coignet LJ, Abraham SM, et al. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene. 1998;16:789-796.
19. Stoppa-Lyonnet D, Soulier J, Lauge A, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91:3920-3926.
20. Rawstron AC, Rollison SJ, Richards S, et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol. 1998;107:148-153.
21. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med. 2000;343:1378-1385.